Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Creative Commons License

Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz I., Alacacioglu A., ...More

BIOMEDICINE & PHARMACOTHERAPY, vol.70, pp.190-195, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70
  • Publication Date: 2015
  • Doi Number: 10.1016/j.biopha.2015.01.019
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.190-195
  • Eskisehir Osmangazi University Affiliated: No


Purpose: Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-kappa B/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis.